HealthcareServices

Necrotizing Enterocolitis Market Insights Report: Opportunities and Drivers 2030

March 2, 2026 by Marketing Posting

Uncover key drivers, emerging technologies, and competitive movements shaping the necrotizing enterocolitis market from 2026–2035 with trusted insights from The Business Research Company

What level of growth is expected in the Necrotizing Enterocolitis Market between 2026 and 2030?

The necrotizing enterocolitis market has seen substantial growth in recent years. It is projected to expand from $5.14 billion in 2025 to $5.47 billion in 2026, achieving a compound annual growth rate (CAGR) of 6.4%. Historically, this expansion has been driven by factors such as a high incidence of premature births, limited neonatal care infrastructure, reliance on broad-spectrum antibiotics, delayed diagnosis in low-resource settings, and the early development of parenteral nutrition.

The necrotizing enterocolitis market is anticipated to exhibit robust expansion over the next few years, with its size projected to reach $6.95 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 6.1%. This growth during the forecast period can be ascribed to increased investment in neonatal intensive care units, progress in regenerative and stem cell therapies, heightened awareness of early NEC detection, the rising adoption of precision nutrition therapies, and the broadening scope of neonatal imaging innovations. Significant trends expected during this period include the growing acceptance of probiotics and prebiotics for NEC prevention, a greater emphasis on early diagnosis and screening in premature infants, expanding utilization of individualized TPN solutions, the proliferation of minimally invasive surgical interventions, and continuous advancements in neonatal critical care and monitoring.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=22068&type=smp

Which Drivers Are Expected To Impact The Necrotizing Enterocolitis Market During The Forecast Period?

A projected increase in premature birth incidents is set to advance the necrotizing enterocolitis market. Premature births, also known as preterm births, signify the delivery of a baby before 37 weeks of gestation, in contrast to the typical 40-week pregnancy term. The rising prevalence of premature births is linked to maternal health conditions such as high blood pressure, diabetes, and infections, which heighten the risk of preterm labor. Additionally, lifestyle factors including smoking, drug use, and insufficient nutrition contribute to a greater likelihood of premature deliveries. A surge in premature births results in more cases of necrotizing enterocolitis (NEC) because premature infants have undeveloped gastrointestinal systems, increasing their susceptibility to inflammation and infection. For instance, in January 2024, as per the Centers for Disease Control and Prevention, a US-based government agency, premature births represent 8.67% of total births in the United States each year. Thus, the growing number of premature births is a key factor propelling the expansion of the necrotizing enterocolitis market.

Which Segments Are Driving Activity In The Necrotizing Enterocolitis Market?

The necrotizing enterocolitis market covered in this report is segmented –

1) By Treatment: Total Parenteral Nutrition (TPN), Gastrointestinal Decompression, Antimicrobial Therapy, Antifungal Treatment, Paracentesis, Other Treatments

2) By Diagnosis: Laboratory Tests, Imaging Techniques

3) By Stage: Stage I (Suspected Necrotizing Enterocolitis), Stage II (Definite Necrotizing Enterocolitis), Stage III (Advanced Necrotizing Enterocolitis)

4) By End-User: Hospitals, Neonatal Intensive Care Units (NICUs), Specialty Clinics

Subsegments:

1) By Total Parenteral Nutrition (TPN): Standard TPN Formulations, Customized Or Individualized TPN Solutions, Lipid Emulsions For TPN, Protein And Amino Acid Supplements In TPN, Micronutrient And Electrolyte-Enhanced TPN

2) By Gastrointestinal Decompression: Nasogastric Tube (NG Tube) Decompression, Orogastric Tube Decompression, Surgical Gastrostomy For Decompression, Non-Surgical Decompression Techniques

3) By Antimicrobial Therapy: Broad-Spectrum Antibiotics, Gram-Positive Coverage Antibiotics, Gram-Negative Coverage Antibiotics, Combination Antibiotic Therapy, Prophylactic Antibiotic Strategies For High-Risk Neonates

4) By Antifungal Treatment: Systemic Antifungal Therapy, Prophylactic Antifungal Therapy For Preterm Infants, Combination Antifungal And Antibiotic Therapy For Severe NEC

5) By Paracentesis: Diagnostic Paracentesis, Therapeutic Paracentesis, Guided Paracentesis using Ultrasound Or Radiological Techniques

6) By Other Treatments: Probiotics And Prebiotics for NEC Prevention, Surgical Interventions, Stem Cell Therapy And Regenerative Medicine Approaches, Immunomodulatory Therapies, Supportive Care

What Industry Trends Are Transforming The Necrotizing Enterocolitis Market?

Leading companies within the necrotizing enterocolitis market are dedicated to developing novel product solutions, including cell-free sterile biologic solutions, to fulfill the pressing need for effective treatments and enhance outcomes for premature infants. Such a solution is a purified, sterile liquid comprising bioactive molecules like proteins, growth factors, and cytokines, derived from cultured cells but entirely free of intact cells, engineered to facilitate healing and diminish inflammation. For example, in December 2023, Noveome Biotherapeutics, Inc., a US-based biopharmaceutical firm, obtained clearance from the U.S. Food and Drug Administration (FDA) to commence its Phase 1-2 clinical trial for ST266, an innovative biologic intended for the treatment of necrotizing enterocolitis (NEC) in premature infants. This represents a significant achievement, as ST266 is poised to be the initial major therapeutic advancement for NEC in over 30 years, thereby addressing a crucial medical demand given the high morbidity and mortality rates of the disease among vulnerable populations.

Which Major Firms Are Strengthening Their Position In The Necrotizing Enterocolitis Market?

Major companies operating in the necrotizing enterocolitis market are Abbott Laboratories, Astellas Pharma Inc., Mayo Foundation for Medical Education and Research, Cleveland Clinic, Boston Children’s Hospital, Hollister Incorporated, UPMC Children’s Hospital of Pittsburgh, Prolacta Bioscience Inc., Evolve BioSystems, Sigma-Tau Pharmaceuticals, Mead Johnson & Company LLC, Liminal BioSciences Inc., Noveome Biotherapeutics Inc., Infant Bacterial Therapeutics, Prometic Life Sciences Inc., Nexilico, Siolta Therapeutics, ProThera Biologics Inc., Plakous Therapeutics Inc., Chosen Diagnostics Inc.

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/necrotizing-enterocolitis-global-market-report

Which Global Regions Are Shaping The Competitive Landscape Of The Necrotizing Enterocolitis Market?

North America was the largest region in the necrotizing enterocolitis market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the necrotizing enterocolitis market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Necrotizing Enterocolitis Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=22068&type=smp

Browse Through More Reports Similar to the Global Necrotizing Enterocolitis Market 2026, By The Business Research Company

Viral Gastroenteritis Market Report 2026

https://www.thebusinessresearchcompany.com/report/viral-gastroenteritis-global-market-report

Gastrointestinal Pathogen Testing Market Report 2026

https://www.thebusinessresearchcompany.com/report/gastrointestinal-pathogen-testing-global-market-report

Hospice Care Market Report 2026

https://www.thebusinessresearchcompany.com/report/hospice-care-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795